NYSE:BDX - Becton Dickinson and Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $242.08 +5.97 (+2.53 %) (As of 01/21/2019 01:14 PM ET)Previous Close$236.11Today's Range$236.3001 - $242.2552-Week Range$208.62 - $265.87Volume1.35 million shsAverage Volume1.05 million shsMarket Capitalization$64.94 billionP/E Ratio21.99Dividend Yield1.27%Beta1.21 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey. Receive BDX News and Ratings via Email Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BDX Previous Symbol CUSIP07588710 Webwww.bd.com Phone201-847-6800Debt Debt-to-Equity Ratio0.90 Current Ratio1.03 Quick Ratio0.69Price-To-Earnings Trailing P/E Ratio21.99 Forward P/E Ratio19.99 P/E Growth1.74 Sales & Book Value Annual Sales$15.98 billion Price / Sales4.06 Cash Flow$18.2289 per share Price / Cash Flow13.28 Book Value$78.25 per share Price / Book3.09Profitability EPS (Most Recent Fiscal Year)$11.01 Net Income$311 million Net Margins1.47% Return on Equity13.88% Return on Assets5.40%Miscellaneous Employees76,032 Outstanding Shares268,260,000Market Cap$64.94 billion OptionableOptionable Becton Dickinson and (NYSE:BDX) Frequently Asked Questions What is Becton Dickinson and's stock symbol? Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX." How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and? Becton Dickinson and announced a quarterly dividend on Monday, November 19th. Investors of record on Monday, December 10th will be paid a dividend of $0.77 per share on Monday, December 31st. This represents a $3.08 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Friday, December 7th. This is a boost from Becton Dickinson and's previous quarterly dividend of $0.75. View Becton Dickinson and's Dividend History. How were Becton Dickinson and's earnings last quarter? Becton Dickinson and Co (NYSE:BDX) released its quarterly earnings data on Tuesday, November, 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $2.93. The medical instruments supplier earned $4.40 billion during the quarter, compared to analysts' expectations of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The business's revenue was up 39.0% on a year-over-year basis. During the same quarter last year, the business posted $2.40 EPS. View Becton Dickinson and's Earnings History. When is Becton Dickinson and's next earnings date? Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Becton Dickinson and. How can I listen to Becton Dickinson and's earnings call? Becton Dickinson and will be holding an earnings conference call on Tuesday, February 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. What guidance has Becton Dickinson and issued on next quarter's earnings? Becton Dickinson and issued an update on its FY19 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $12.05 to $12.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.62. The company issued revenue guidance of $17.34 billion to $17.50 billion, compared to the consensus revenue estimate of $17.70 billion.Becton Dickinson and also updated its FY 2019 guidance to $12.05-12.15 EPS. What price target have analysts set for BDX? 11 analysts have issued twelve-month price objectives for Becton Dickinson and's stock. Their forecasts range from $175.00 to $280.00. On average, they anticipate Becton Dickinson and's stock price to reach $251.9091 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View Analyst Price Targets for Becton Dickinson and. What is the consensus analysts' recommendation for Becton Dickinson and? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Becton Dickinson and. Has Becton Dickinson and been receiving favorable news coverage? News stories about BDX stock have trended positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Becton Dickinson and earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. Who are some of Becton Dickinson and's key competitors? Some companies that are related to Becton Dickinson and include 3M (MMM), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD) and Novocure (NVCR). Who are Becton Dickinson and's key executives? Becton Dickinson and's management team includes the folowing people: Mr. Vincent A. Forlenza, Chairman & CEO (Age 66)Mr. Thomas E. Polen Jr., Pres & COO (Age 46)Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 62)Mr. Samrat S. Khichi, Exec. VP & Gen. Counsel (Age 52)Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 56) Who are Becton Dickinson and's major shareholders? Becton Dickinson and's stock is owned by a number of of retail and institutional investors. Top institutional investors include Waverton Investment Management Ltd (0.18%), BTIM Corp. (0.18%), Douglass Winthrop Advisors LLC (0.11%), Atalanta Sosnoff Capital LLC (0.10%), Alta Capital Management LLC (0.05%) and James Hambro & Partners (0.04%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, Charles R Bodner, David F Melcher, Ellen R Strahlman, Gary M Cohen, James C Lim, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr, Timothy M Ring and Vincent A Forlenza. View Institutional Ownership Trends for Becton Dickinson and. Which institutional investors are selling Becton Dickinson and stock? BDX stock was sold by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Sit Investment Associates Inc., Gulf International Bank UK Ltd, BTIM Corp., State of Alaska Department of Revenue, Campbell Newman Asset Management Inc., Saratoga Research & Investment Management and DNB Asset Management AS. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Charles R Bodner, James C Lim, James W Borzi, John E Gallagher, Nabil Shabshab, Ribo Alberto Mas, Thomas E Polen Jr, Timothy M Ring and Vincent A Forlenza. View Insider Buying and Selling for Becton Dickinson and. Which institutional investors are buying Becton Dickinson and stock? BDX stock was acquired by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Advisors Capital Management LLC, Patriot Wealth Management Inc., James Hambro & Partners, Douglass Winthrop Advisors LLC, Steward Partners Investment Advisory LLC, Granite Investment Advisors LLC and Landsberg Bennett & Dubbaneh LLC. View Insider Buying and Selling for Becton Dickinson and. How do I buy shares of Becton Dickinson and? Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Becton Dickinson and's stock price today? One share of BDX stock can currently be purchased for approximately $242.08. How big of a company is Becton Dickinson and? Becton Dickinson and has a market capitalization of $64.94 billion and generates $15.98 billion in revenue each year. The medical instruments supplier earns $311 million in net income (profit) each year or $11.01 on an earnings per share basis. Becton Dickinson and employs 76,032 workers across the globe. What is Becton Dickinson and's official website? The official website for Becton Dickinson and is http://www.bd.com. How can I contact Becton Dickinson and? Becton Dickinson and's mailing address is ONE BECTON DR, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800. MarketBeat Community Rating for Becton Dickinson and (NYSE BDX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 430 (Vote Outperform)Underperform Votes: 507 (Vote Underperform)Total Votes: 937MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is a Swap?